- Home
- EGY vs IGMS Comparison
EGY vs IGMS Comparison
Compare EGY & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGY
- IGMS
- Stock Information
- Founded
- EGY 1985
- IGMS 1993
- Country
- EGY United States
- IGMS United States
- Employees
- EGY N/A
- IGMS N/A
- Industry
- EGY Oil & Gas Production
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- EGY Energy
- IGMS Health Care
- Exchange
- EGY Nasdaq
- IGMS Nasdaq
- Market Cap
- EGY 497.4M
- IGMS 528.6M
- IPO Year
- EGY N/A
- IGMS 2019
- Fundamental
- Price
- EGY $4.69
- IGMS $7.55
- Analyst Decision
- EGY Strong Buy
- IGMS Buy
- Analyst Count
- EGY 1
- IGMS 8
- Target Price
- EGY $8.00
- IGMS $16.25
- AVG Volume (30 Days)
- EGY 1.0M
- IGMS 213.0K
- Earning Date
- EGY 11-11-2024
- IGMS 11-08-2024
- Dividend Yield
- EGY 5.31%
- IGMS N/A
- EPS Growth
- EGY 170.05
- IGMS N/A
- EPS
- EGY 0.86
- IGMS N/A
- Revenue
- EGY $506,421,000.00
- IGMS $2,918,000.00
- Revenue This Year
- EGY $0.48
- IGMS $386.95
- Revenue Next Year
- EGY N/A
- IGMS N/A
- P/E Ratio
- EGY $5.48
- IGMS N/A
- Revenue Growth
- EGY 25.82
- IGMS 57.64
- 52 Week Low
- EGY $4.03
- IGMS $6.17
- 52 Week High
- EGY $7.51
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- EGY 32.96
- IGMS 31.94
- Support Level
- EGY $4.74
- IGMS $7.00
- Resistance Level
- EGY $5.08
- IGMS $10.80
- Average True Range (ATR)
- EGY 0.18
- IGMS 1.02
- MACD
- EGY -0.00
- IGMS -0.10
- Stochastic Oscillator
- EGY 21.91
- IGMS 10.39
About EGY VAALCO Energy Inc.
VAALCO Energy Inc is an independent energy company operating in the United States. It is principally engaged in the acquisition, exploration, development, and production of crude oil and natural gas. The company operates through geographical segments namely Gabon, Egypt, Canada, Equatorial Guinea and Corporate and Other. The company generates maximum revenue from the Gabon segment.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.